AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29265833 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on both symptomatology and alliance
Number of subjects: 547
Study 29265833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambert's OQ progress feedback report
Number of subjects: 547
Study 29265833 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback (low symptomatology)
Number of subjects: 547
Study 29265833 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback (high symptomatology)
Number of subjects: 547
Study 28384828 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days)
Number of subjects: 379
Study 28384828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 28384828 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 379
Study 25117853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 1 g/day
Number of subjects: 5
Study 25117853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 3 g/day
Number of subjects: 5
Study 25117853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 6 g/day
Number of subjects: 5
Study 23835026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT) after intravenous thrombolysis (IVT)
Number of subjects: 750
Study 23835026 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical care alone
Number of subjects: 750
Study 21993064 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (10 ml of 0.2%)
Number of subjects: 50
Study 21993064 — intervention group
Group type: COMPARATOR
Intervention: Cacao bean husk extract mouthrinse (10 ml of 0.1%)
Number of subjects: 50
Study 18785254 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 10 mg daily
Number of subjects: 941
Study 18785254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study 16541325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, fluoracil (CMF) chemotherapy
Number of subjects: 317
Study 16541325 — intervention group
Group type: COMPARATOR
Intervention: Ovarian ablation by oophorectomy
Number of subjects: 317
Study 16541325 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy
Number of subjects: 317
Study 12925248 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day for 72 hours
Number of subjects: 34
Study 12925248 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 34
Study 12925248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 to 80 mg intravenously during surgery)
Number of subjects: 34
Study 11004140 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 825
Study 11004140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study 8666957 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidimensional rating task preceding pairwise dissimilarity ratings
Number of subjects: 3
Study 8666957 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-s delay between presentation of pair members
Number of subjects: 3
Study 8666957 — intervention group
Group type: EXPERIMENTAL
Intervention: Global effects of density modeled by extending A. Parducci's range-frequency theory
Number of subjects: 3
Study 8666957 — intervention group
Group type: EXPERIMENTAL
Intervention: Local density effects
Number of subjects: 3
Study 1296466 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional programme intervention
Number of subjects: 0
Study 1296466 — intervention group
Group type: COMPARATOR
Intervention: Control-placebo group
Number of subjects: 0
Study 6150902 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (300 micrograms/60 min)
Number of subjects: 6
Study 6150902 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (600 micrograms/60 min)
Number of subjects: 6
Study 6150902 — intervention group
Group type: EXPERIMENTAL
Intervention: prenalterol (1 mg/60 min)
Number of subjects: 6
Study 6150902 — intervention group
Group type: EXPERIMENTAL
Intervention: prenalterol (2 mg/60 min)
Number of subjects: 6
Study 31609774 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 250
Study 31609774 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 250
Study 29129457 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (GECS) 18‐21 mmHg at the ankle level (n=15)
Number of subjects: 30
Study 29129457 — intervention group
Group type: COMPARATOR
Intervention: Placebo stocking (0 mmHg, n=15)
Number of subjects: 30
Study 29129457 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (GECS)
Number of subjects: 30
Study 29129457 — intervention group
Group type: COMPARATOR
Intervention: Placebo stocking
Number of subjects: 30
Study 27842163 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy (Bevacizumab and Ranibizumab) administered monthly for 6 months
Number of subjects: 89
Study 23793234 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n = 72)
Number of subjects: 140
Study 23793234 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 68)
Number of subjects: 140
Study 22215059 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue
Number of subjects: 58
Study 22215059 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 58
Study 20724937 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypertension
Number of subjects: 31495
Study 20724937 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension
Number of subjects: 31495
Study 20724937 — intervention group
Group type: EXPERIMENTAL
Intervention: Common mental disorder (GHQ-12 score of ≥4)
Number of subjects: 31495
Study 20724937 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosed hypertension with common mental disorder
Number of subjects: 31495
Study 20724937 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension with common mental disorder
Number of subjects: 31495
Study 20724937 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed (untreated) hypertension with common mental disorder
Number of subjects: 31495
Study 17954953 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/day
Number of subjects: 157
Study 17954953 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day
Number of subjects: 157
Study 15808167 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsil IOL with a sharp optic edge design (model S)
Number of subjects: 51
Study 15808167 — intervention group
Group type: COMPARATOR
Intervention: Microsil IOL with a round optic edge design (model R)
Number of subjects: 51
Study 15808167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOL groups
Number of subjects: 51
Study 12160813 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL lignocaine 2% with sodium hyaluronidase 150 IU/mL
Number of subjects: 100
Study 12160813 — intervention group
Group type: COMPARATOR
Intervention: 5 mL plain lignocaine 2%
Number of subjects: 100
Study 11562930 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Counselor
Number of subjects: 29
Study 11562930 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Computer Program
Number of subjects: 29
Study 9129047 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) 100 microg/m2
Number of subjects: 9
Study 9129047 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) 50 microg/m2
Number of subjects: 9
Study 9129047 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma)
Number of subjects: 9
Study 7893592 — intervention group
Group type: EXPERIMENTAL
Intervention: Post tetracosactrin levels of plasma and salivary cortisol
Number of subjects: 20
Study 7893592 — intervention group
Group type: EXPERIMENTAL
Intervention: Post CRH-LVP levels of plasma ACTH and LPH
Number of subjects: 20
Study 7893592 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of 08.00 h salivary cortisol
Number of subjects: 20
Study 7893592 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of 08.00 h plasma cortisol
Number of subjects: 20
Study 7893592 — intervention group
Group type: EXPERIMENTAL
Intervention: Post metyrapone levels of plasma 11-deoxycortisol, ACTH, LPH and beta-endorphin
Number of subjects: 20
Study 3677281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate 1% with epinephrine 1/400,000
Number of subjects: 60
Study 3677281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% with epinephrine 1/400,000
Number of subjects: 60
Study 3677281 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine 1% with epinephrine 1/400,000
Number of subjects: 60
Study 3677281 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 29693796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 30 mg/m2/day
Number of subjects: 41
Study 29693796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg/m2/day
Number of subjects: 41
Study 29693796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 55 mg/m2/day
Number of subjects: 41
Study 29693796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (all dose levels)
Number of subjects: 41
Study 26916566 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod 4 mg after 192 hours of discontinuation
Number of subjects: 138
Study 26916566 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod (various doses) after up to 96 hours of discontinuation
Number of subjects: 138
Study 26916566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 26916566 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod (various doses)
Number of subjects: 138
Study 25594427 — intervention group
Group type: EXPERIMENTAL
Intervention: CT327 (TrkA inhibitor)
Number of subjects: 160
Study 25594427 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 160
Study 23099100 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support tools in the EHR delivered to primary care providers at the point of care
Number of subjects: 800
Study 23099100 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support tools in the EHR with direct-to-parent support (telephone coaching and twice-weekly text messages)
Number of subjects: 800
Study 23099100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 800
Study 20176986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 6801
Study 20176986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6801
Study 20176986 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (meta-analysis)
Number of subjects: 6801
Study 17522613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free milk
Number of subjects: 33
Study 17522613 — intervention group
Group type: COMPARATOR
Intervention: Ordinary milk
Number of subjects: 33
Study 16766116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Number of subjects: 268
Study 16766116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10mg
Number of subjects: 268
Study 16766116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 12478068 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus hydroxyurea (HU)
Number of subjects: 20
Study 12478068 — intervention group
Group type: COMPARATOR
Intervention: HAART
Number of subjects: 20
Study 10861881 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing pure oxygen
Number of subjects: 9
Study 10861881 — intervention group
Group type: COMPARATOR
Intervention: Breathing pure oxygen without breath-hold
Number of subjects: 9
Study 10861881 — intervention group
Group type: COMPARATOR
Intervention: Breathing pure oxygen with breath-hold
Number of subjects: 9
Study 10861881 — intervention group
Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 9
Study 8677865 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (n = 911; 33%)
Number of subjects: 2723
Study 8677865 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker therapy (n = 1,812; 67%)
Number of subjects: 2723
Study 8677865 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 2723
Study 1355798 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10(6), 5 x 10(7), 5 x 10(8), 5 x 10(9), or 1 x 10(10) CFU)
Number of subjects: 412
Study 1355798 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10(8) CFU)
Number of subjects: 412
Study 1355798 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10(9) CFU)
Number of subjects: 412
Study 1355798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 x 10(8) inactivated Escherichia coli K-12)
Number of subjects: 412
Study 31584677 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief admission to hospital by self-referral
Number of subjects: 0
Study 31584677 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29742655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200-3,000 mg/d)
Number of subjects: 89
Study 29742655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 26912177 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-building intervention
Number of subjects: 0
Study 26912177 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% price reductions
Number of subjects: 0
Study 26912177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (skill-building + 20% price reductions)
Number of subjects: 0
Study 26912177 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-building resources
Number of subjects: 0
Study 26912177 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24152706 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) loading (5 g of Cr + 10 g of fructose, four times daily for 5 days)
Number of subjects: 12
Study 24152706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 g of fructose, four times daily for 5 days)
Number of subjects: 12
Study 24152706 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) loading
Number of subjects: 12
Study 23155026 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 2,650 kcal of AME(n)/kg
Number of subjects: 130
Study 23155026 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 2,750 kcal of AME(n)/kg
Number of subjects: 130
Study 23155026 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 2,850 kcal of AME(n)/kg
Number of subjects: 130
Study 23155026 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 2,950 kcal of AME(n)/kg
Number of subjects: 130
Study 23155026 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier hens (1,733 g)
Number of subjects: 130
Study 23155026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter hens (1,606 g)
Number of subjects: 130
Study 20538329 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 12
Study 20538329 — intervention group
Group type: COMPARATOR
Intervention: Diluent inhalation
Number of subjects: 12
Study 17960305 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/Heavy drinking partners
Number of subjects: 102
Study 17960305 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network with drinkers
Number of subjects: 102
Study 16260701 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNalpha and isotretinoin (206 patients)
Number of subjects: 407
Study 16260701 — intervention group
Group type: COMPARATOR
Intervention: IFNalpha and placebo (201 patients)
Number of subjects: 407
Study 16259830 — intervention group
Group type: EXPERIMENTAL
Intervention: Current users of hormone replacement therapy (HRT)
Number of subjects: 124
Study 16259830 — intervention group
Group type: COMPARATOR
Intervention: Non-users of hormone replacement therapy (HRT)
Number of subjects: 124
Study 16259830 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 124
Study 9530793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 219
Study 9530793 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxants
Number of subjects: 219
Study 9530793 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotics
Number of subjects: 219
Study 9530793 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 219
Study 8681495 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (440 mg/two times per day for 7 days)
Number of subjects: 20
Study 8681495 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg/two times per day for 7 days) plus metronidazole (250 mg/three times per day for 7 days)
Number of subjects: 20
Study 2229783 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning group (n = 84)
Number of subjects: 111
Study 2229783 — intervention group
Group type: COMPARATOR
Intervention: Testing group (n = 27)
Number of subjects: 111
Study 390158 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (GABA analogue)
Number of subjects: 0
Study 30982748 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (HRW) 1 L per day for 28 days
Number of subjects: 12
Study 30982748 — intervention group
Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 12
Study 28912958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered mental health intervention (six individual sessions)
Number of subjects: 60
Study 28912958 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 60
Study 26055855 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesicoureteral reflux (VUR)
Number of subjects: 500
Study 26055855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder and bowel dysfunction (BBD)
Number of subjects: 500
Study 26055855 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of renal scarring on baseline scan
Number of subjects: 500
Study 26055855 — intervention group
Group type: COMPARATOR
Intervention: No VUR
Number of subjects: 500
Study 26055855 — intervention group
Group type: EXPERIMENTAL
Intervention: VUR
Number of subjects: 500
Study 23926208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting remnant cholesterol
Number of subjects: 60608
Study 23926208 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 60608
Study 21878535 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + AS1402 (9 mg/kg weekly infusion)
Number of subjects: 110
Study 21878535 — intervention group
Group type: COMPARATOR
Intervention: Letrozole only (2.5 mg daily)
Number of subjects: 110
Study 21878535 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + AS1402
Number of subjects: 110
Study 19214676 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV antigen positive group
Number of subjects: 70
Study 19214676 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV antigen
Number of subjects: 70
Study 19214676 — intervention group
Group type: COMPARATOR
Intervention: anti‐HEV IgM positive group
Number of subjects: 70
Study 19214676 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV RNA
Number of subjects: 70
Study 19214676 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐HEV IgM
Number of subjects: 70
Study 17950094 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 150 mg/d
Number of subjects: 28
Study 17950094 — intervention group
Group type: COMPARATOR
Intervention: Mitiglinide 30 mg/d
Number of subjects: 28
Study 17147758 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive push translation strategies such as reminders
Number of subjects: 0
Study 17147758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the intervention
Number of subjects: 0
Study 11332926 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (20 mg elemental)
Number of subjects: 96
Study 11332926 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus Vitamin A
Number of subjects: 96
Study 11332926 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 96
Study 11332926 — intervention group
Group type: COMPARATOR
Intervention: Control (neither zinc nor vitamin A)
Number of subjects: 96
Study 11332926 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 96
Study 9110923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg once daily)
Number of subjects: 23
Study 9110923 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (200 mg once daily)
Number of subjects: 23
Study 7962886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 64
Study 7962886 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (RT)
Number of subjects: 64
Study 7962886 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact control (MCC)
Number of subjects: 64
Study 3117082 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane and nitrous oxide
Number of subjects: 21
Study 3117082 — intervention group
Group type: COMPARATOR
Intervention: halothane and nitrous oxide
Number of subjects: 21
Study 30689621 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (vitrectomy within 4 days)
Number of subjects: 53
Study 30689621 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery (vitrectomy between 10-14 days)
Number of subjects: 53
Study 30689621 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 53
Study 30689621 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery
Number of subjects: 53
Study 31248425 — intervention group
Group type: EXPERIMENTAL
Intervention: Group antenatal care
Number of subjects: 0
Study 28202033 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise lactate kinetics-oriented hemodynamic therapy
Number of subjects: 360
Study 28202033 — intervention group
Group type: COMPARATOR
Intervention: ScvO2-oriented hemodynamic therapy
Number of subjects: 360
Study 26387028 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading-dose rosuvastatin 20 mg 12 hours prior to PCI, with a second dose just before PCI.
Number of subjects: 126